Regenerex Pharma (Regenerex Pharma) Short-Term Capital Lease Obligation : $0.15 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Short-Term Capital Lease Obligation?

Regenerex Pharma's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.15 Mil.

Regenerex Pharma's quarterly Short-Term Capital Lease Obligation increased from Jun. 2023 ($0.14 Mil) to Sep. 2023 ($0.16 Mil) but then declined from Sep. 2023 ($0.16 Mil) to Dec. 2023 ($0.15 Mil).

Regenerex Pharma Short-Term Capital Lease Obligation Historical Data

The historical data trend for Regenerex Pharma's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Short-Term Capital Lease Obligation Chart

Regenerex Pharma Annual Data

Trend

Nov09

Nov10

Nov11

Nov12

Nov13

Nov14

Mar17

Mar18

Mar22

Mar23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

Regenerex Pharma Quarterly Data
	May14	Aug14	Nov14	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	0.14	0.16	0.15

Regenerex Pharma Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Regenerex Pharma Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerex Pharma (Regenerex Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108

Website

https://regenerexpharmainc.com

Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines